309 related articles for article (PubMed ID: 27561756)
1. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.
Nota NM; Dekker MJHJ; Klaver M; Wiepjes CM; van Trotsenburg MA; Heijboer AC; den Heijer M
Andrologia; 2017 Aug; 49(6):. PubMed ID: 27561756
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
3. Effects of cross-sex hormone treatment on cortical thickness in transsexual individuals.
Zubiaurre-Elorza L; Junque C; Gómez-Gil E; Guillamon A
J Sex Med; 2014 May; 11(5):1248-61. PubMed ID: 24617977
[TBL] [Abstract][Full Text] [Related]
4. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals.
Bunck MC; Giltay EJ; Diamant M; Gooren LJ; Teerlink T
Atherosclerosis; 2009 Sep; 206(1):245-50. PubMed ID: 19324362
[TBL] [Abstract][Full Text] [Related]
6. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.
Defreyne J; Nota N; Pereira C; Schreiner T; Fisher AD; den Heijer M; T'Sjoen G
LGBT Health; 2017 Oct; 4(5):328-336. PubMed ID: 28880825
[TBL] [Abstract][Full Text] [Related]
7. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
[TBL] [Abstract][Full Text] [Related]
9. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
[TBL] [Abstract][Full Text] [Related]
10. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
[TBL] [Abstract][Full Text] [Related]
11. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
[TBL] [Abstract][Full Text] [Related]
12. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.
Collet S; Gieles NC; Wiepjes CM; Heijboer AC; Reyns T; Fiers T; Lapauw B; den Heijer M; T'Sjoen G
J Clin Endocrinol Metab; 2023 Jan; 108(2):331-338. PubMed ID: 36201493
[TBL] [Abstract][Full Text] [Related]
13. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
14. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals.
Asscheman H; Gooren LJ; Assies J; Smits JP; de Slegte R
Clin Endocrinol (Oxf); 1988 Jun; 28(6):583-8. PubMed ID: 2978262
[TBL] [Abstract][Full Text] [Related]
15. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
[TBL] [Abstract][Full Text] [Related]
16. Effects of sex steroids on the pattern of methylation and expression of the promoter region of estrogen and androgen receptors in people with gender dysphoria under cross-sex hormone treatment.
Aranda G; Fernández-Rebollo E; Pradas-Juni M; Hanzu FA; Kalko SG; Halperin I; Mora M
J Steroid Biochem Mol Biol; 2017 Sep; 172():20-28. PubMed ID: 28539237
[TBL] [Abstract][Full Text] [Related]
17. Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF).
Fuss J; Hellweg R; Van Caenegem E; Briken P; Stalla GK; T'Sjoen G; Auer MK
Eur Neuropsychopharmacol; 2015 Jan; 25(1):95-9. PubMed ID: 25498415
[TBL] [Abstract][Full Text] [Related]
18. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
Liang JJ; Jolly D; Chan KJ; Safer JD
Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822
[TBL] [Abstract][Full Text] [Related]
19. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual.
García-Malpartida K; Martín-Gorgojo A; Rocha M; Gómez-Balaguer M; Hernández-Mijares A
Fertil Steril; 2010 Aug; 94(3):1097.e13-5. PubMed ID: 20227072
[TBL] [Abstract][Full Text] [Related]
20. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
